Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multicenter Prospective Randomized Controlled Trial of Plicated Laparoscopic Adjustable Gastric Banding

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01564732
Recruitment Status : Terminated (Sponsor withdrew funding.)
First Posted : March 28, 2012
Results First Posted : June 1, 2016
Last Update Posted : July 1, 2016
Sponsor:
Collaborator:
Allergan
Information provided by (Responsible Party):
Dana Portenier, MD, Duke University

Tracking Information
First Submitted Date  ICMJE March 7, 2012
First Posted Date  ICMJE March 28, 2012
Results First Submitted Date  ICMJE April 25, 2016
Results First Posted Date  ICMJE June 1, 2016
Last Update Posted Date July 1, 2016
Study Start Date  ICMJE September 2013
Actual Primary Completion Date April 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 26, 2012)
Weight Loss [ Time Frame: 36 months ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 29, 2013)
  • Quality of Life [ Time Frame: 36 months ]
  • Quantitative Change in Hypertension [ Time Frame: 36 months ]
    Systolic and Diastolic Blood Pressure will be measured over the scheduled visits and the change in preoperative and postoperative blood pressure will be determined. We will also assess the need for medications to treat hypertension before and after surgery.
  • Quantitative Change in Diabetes [ Time Frame: 36 months ]
    Blood Sugar will be measured over the scheduled visits and the change in preoperative and postoperative glucose levels will be determined. We will also assess the need for medications to treat diabetes before and after surgery.
  • Quantitative Change in Hyperlipidemia [ Time Frame: 36 months ]
    Lipid levels will be measured annually for 3 years and the change in preoperative and postoperative levels will be determined. We will also assess the need for medications to treat hyperlipidemia before and after surgery.
  • Quantitative Change in Hypertriglyceridemia [ Time Frame: 36 months ]
    Triglyceride levels will be measured annually for 3 years and the change in preoperative and postoperative levels will be determined. We will also assess the need for medications to treat hypertriglyceridemia before and after surgery.
Original Secondary Outcome Measures  ICMJE
 (submitted: March 26, 2012)
  • Quality of Life [ Time Frame: 36 months ]
  • Quantitative Change in Hypertension [ Time Frame: 36 months ]
    Systolic and Diastolic Blood Pressure will be measured over the scheduled visits and the change in preoperative and postoperative blood pressure will be determined. We will also assess the need for medications to treat hypertension before and after surgery.
  • Quantitative Change in Diabetes [ Time Frame: 36 months ]
    Blood Sugar will be measured over the scheduled visits and the change in preoperative and postoperative glucose levels will be determined. We will also assess the need for medications to treat diabetes before and after surgery.
  • Quantitative Change in Hyperlipidemia [ Time Frame: 36 months ]
    Lipid levels will be measured annualy for 3 years and the change in preoperative and postoperative levels will be determined. We will also assess the need for medications to treat hyperlipidemia before and after surgery.
  • Quantitative Change in Hypertriglyceridemia [ Time Frame: 36 months ]
    Triglyceride levels will be measured annualy for 3 years and the change in preoperative and postoperative levels will be determined. We will also assess the need for medications to treat hypertriglyceridemia before and after surgery.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Multicenter Prospective Randomized Controlled Trial of Plicated Laparoscopic Adjustable Gastric Banding
Official Title  ICMJE Multicenter Prospective Randomized Clinical Trial of Plicated Laparoscopic Adjustable Gastric Banding
Brief Summary The purpose of this study is to compare plicated laparoscopic adjustable gastric banding (PLAGB) to standard laparoscopic adjustable gastric banding (SLAGB) in a prospective randomized clinical trial. We hypothesize the plicated procedure will provide greater short- and long-term excess weight loss than the standard procedure. There exists little prospective randomized data regarding this topic and the recent position statement from the American Society for Metabolic and Bariatric Surgery (ASMBS) encourages this type of study. Further information on background and design of this study are provided in the detailed description.
Detailed Description

Morbid obesity is a major problem affecting the lives of millions in the US. As of 2008, overall prevalence of obesity as defined by body mass index (BMI) greater than 30 kg/m2 was 33.8%.1 Obesity adversely affects the lives of millions of Americans by increasing the risk for co-morbid conditions such as diabetes mellitus, obstructive sleep apnea, hypertension, and even certain cancers.2-4 The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.4,5

One of the biggest drawbacks to LAGB [when compared to the 'gold standard' of bariatric surgery: Roux-en-Y gastric bypass] is that patients tend to have a slower, less dramatic weight loss in the first few months after surgery.5-7 In addition, the LAGB procedure is associated with an approximate 3% chance of "band slippage" complications.8 In order to address some of these issues modifications in the technique of LAGB surgery have been made. Techniques such as a "pars-flaccida approach" to tissue dissection and the placement of plication sutures to "anchor" the redundant stomach around the newly placed band device were introduced and shown to have positive results in reducing band complication rates.8 More recently, sleeve gastrostomy procedures (the greater curvature and significant portion of the body of the stomach is resected over a sizing bougie; leaving a narrow 'sleeve' of stomach) have also become popular in treating patients with morbid obesity.9 Combining these concepts, a modified technique of plicated LAGB was introduced.

At the time of LAGB placement, plication sutures can be placed along the body & greater curvature of the stomach to "tighten" and "cinch up" the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss.8

However, as of today there exists no prospective, randomized study that compares the outcomes of this modified surgical technique to the standard procedure (SLAGB).

This is a prospective randomized clinical trial comparing PLAGB versus SLAGB. All adult (age older than 18 years) morbidly obese patients meeting NIH criteria for bariatric surgery (BMI > 35 + co-morbid disease or BMI > 40) who are undergoing bariatric surgery at the Duke Metabolic and Weight Loss Surgery Center and the University of Pittsburgh Medical Center will be recruited. All enrolled patients will be randomly assigned to either the SLAGB (control) group or the PLAGB (study) group. Variables to be studied include patient age, gender, ethnicity, co-morbid disease conditions, height, weight, BMI, intra-operative data such as operative time and blood loss, and post-operative outcomes including length of hospital stay, complication rates, weight loss, and co-morbid disease resolution. In addition, each patient will complete standardized surveys rating their satisfaction from surgery, their quality of life (OWL-QOL-17), and their sleepiness (Epworth Sleepiness Scale) at three distinct time intervals: pre-operatively and at weeks 24 & 48.

Each subject will be followed and data collected according to the following schedule of visits:

Study Visit Schedule:

Year 1:

Visit 1: Screening Visit Visit 2: Day 0 (surgery) Visit 3: Week 2 (+/- 2 days) Visit 4: Week 4 (1 month) Visit 5: Week 8 (2 months) Visit 6: Week 12 (3 months) Visit 7: Week 16 (4 months) Visit 8: Week 20 (5 months) Visit 9: Week 24 (6 months) Visit 10: Week 30 Visit 11: Week 36 Visit 12: Week 42 Visit 13: Week 48

Year 2:

Visit 14: Week 60 Visit 15: Week 72 Visit 16: Week 84 Visit 17: Week 96

Year 3:

Visit 18: Week 128 (2.5 yrs) Visit 19: Week 156 (3 yrs)

Data gathered from PLAGB subjects will be compared to SLAGB controls. Pre- and post-operative care will be delivered consistent with our established protocols and standard practices; without regard to surgical approach. This includes a standard preoperative evaluation and patient education period followed by surgery. After surgery, patients are usually discharged from the hospital within the first 24 hours. Follow-up of patients will include an initial post-discharge clinic visit within the first 2 weeks, and subsequent visits scheduled at the time intervals as listed above. Subjects will be followed for a period of approximately 12 months.

This study compares a modified bariatric surgical approach. PLAGB will be studied and compared to the SLAGB procedure through a prospective randomized clinical trial.

Please note: Per our FDA approved modification of 6/18/2014, all study specific testing was eliminated, and only safety assessments were completed in the surgical office at 6 months and 1 year after surgery.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Condition  ICMJE Morbid Obesity
Intervention  ICMJE
  • Device: Standard-LAGB
    The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.
    Other Name: Standard Laparoscopic Adjustable Gastric Banding Surgery
  • Device: Plicated-LAGB
    At the time of LAGB placement, plication sutures can be placed along the body & greater curvature of the stomach to "tighten" and "cinch up" the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss.
    Other Name: Plicated Laparoscopic Adjustable Gastric Banding Surgery
Study Arms  ICMJE
  • Active Comparator: Standard-LAGB
    Subjects will be blinded and randomly assigned to the Standard Laparoscopic Gastric Banding(SLAGB)arm of the study. These subjects will receive the standard of care or standard laparoscopic gastric banding surgery.Subjects will be followed for a period of approximately 36 months.
    Intervention: Device: Standard-LAGB
  • Experimental: Plicated-LAGB
    Subjects will be blinded and randomly assigned to the Plicated Laparoscopic Gastric Banding(PLAGB)arm of the study. These subjects will receive the plicated laparoscopic gastric banding surgery with involves the placement of plication sutures to "anchor" the redundant stomach around the newly placed device. Subjects will be followed for a period of approximately 36 months.
    Intervention: Device: Plicated-LAGB
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: April 25, 2016)
17
Original Estimated Enrollment  ICMJE
 (submitted: March 26, 2012)
60
Actual Study Completion Date  ICMJE April 2015
Actual Primary Completion Date April 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria: Subjects must meet the following criteria to be eligible for study entry:

  1. Age between 18-60 years,
  2. Morbidly obese:

a. BMI > 40, or b. BMI > 35 + co-morbid obesity related disease condition c)BMI < or equal to 55

Exclusion Criteria: Subjects meeting the following criteria will be excluded from study entry:

  1. Patients with any major medical problems contraindicating surgery (eg.myocardial infarct within last 6 months, cancer within last 5 years, end stage renal/liver disease, etc.)
  2. Patients with a medically treatable cause of obesity (eg. untreated hypothyroidism, Prader-Willi, etc.)
  3. Patients who elect to undergo a surgery other than a PLAGB or SLAGB
  4. Patient who is unwilling to be randomized to PLAGB or SLAGB
  5. Pregnant or planning pregnancy within 12 months
  6. Alcohol or drug addiction
  7. Established infection anywhere in the body at the time of surgery
  8. Previous history of bariatric surgery, gastric surgery, intestinal obstruction, or adhesive peritonitis.
  9. Family or patient history of autoimmune disease
  10. Hiatal Hernia > 3cm (as reported per radiology on pre-operative swallow study)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01564732
Other Study ID Numbers  ICMJE Pro00033638
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Dana Portenier, MD, Duke University
Study Sponsor  ICMJE Dana Portenier, MD
Collaborators  ICMJE Allergan
Investigators  ICMJE
Principal Investigator: Dana D Portenier, MD Duke University
Principal Investigator: Carol McCloskey, MD University of Pittsburgh Medical Center
PRS Account Duke University
Verification Date June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP